Stock Price & Analysis

Based on the recent market data and analysis, here's a direct assessment of ABBV's current trading situation:

Technical Analysis The stock is currently trading at $170.02, showing a slight decline of -0.22% in the regular market session on January 24, 2025. The RSI-14 reading of 40.05 indicates the stock is approaching oversold territory but hasn't reached extreme levels yet. The stock is trading below its 20-day moving average of $175.84, suggesting short-term bearish momentum.

Recent Developments AbbVie has recently made strategic moves to strengthen its portfolio:

• Completed the acquisition of Cerevel Therapeutics to enhance its neuroscience pipeline
• Successfully integrated Aliada Therapeutics, adding potential Alzheimer's treatment to its pipeline
• Positive developments in core products Skyrizi and Rinvoq, which are expected to generate over $27 billion in annual sales within three years

Growth Outlook

• Management has raised full-year revenue guidance to $56 billion
• Analysts project 10-12% annual EPS growth over the next 3 years
• Strong performance in immunology segment with Skyrizi and Rinvoq showing 52% and 47% YoY growth respectively

Buy Signal Indicators

1. Current price represents an attractive entry point after recent pullback from $207 high
2. Forward P/E of 15.9x appears reasonable given growth prospects
3. Solid dividend yield of 3.8% with 11 consecutive years of growth

Based on the technical and fundamental analysis, ABBV appears to be a BUY at current levels. The recent price pullback offers an attractive entry point for both income and growth investors, supported by strong product pipeline and reasonable valuation.

Based on the provided data and market analysis, here is the price prediction for ABBV stock in 2025:

ABBV stock is expected to reach $182-185 by end of 2025, driven by strong growth in Skyrizi and Rinvoq sales which are projected to exceed $27 billion in annual revenue. The recent pullback from $207 to around $170 appears to be an overreaction to the Cerevel acquisition news, creating an attractive entry point. Technical analysis shows the stock has strong support at the Fibonacci level of $169.12 with resistance at $176.70.

The stock's upside is supported by a robust pipeline including promising neuroscience therapies and expanded indications for Botox. Despite Humira's patent expiration impact, ABBV's diversified portfolio and strategic acquisitions position it well for continued growth through 2025.

The S1 support level for ABBV Stock is $169.12 ,The R1 resistant level for ABBV Stock is $176.7.

As of the end of day on 2025-01-24, the price of ABBV Stock was $170.02.

The target price for ABBV Stock according to analyst rating is 203.24, with the highest price target at 240.00 and the lowest at 165.00. Analysts have a Moderate Buy rating on ABBV Stock overall.

The market cap of ABBV is $300.9B.

Based on the provided data and recent market analysis, here's a comprehensive evaluation of ABBV's valuation:

Valuation Analysis ABBV currently shows mixed valuation signals. The stock's Q3 2024 PE ratio of 68.91 is significantly higher than its historical average, suggesting potential overvaluation from a pure earnings multiple perspective. However, this needs to be contextualized with the company's growth prospects and pipeline developments.

Growth Drivers & Pipeline The company demonstrates strong growth potential through:

• Skyrizi and Rinvoq combined sales reached $4.8 billion in Q3, showing impressive YoY growth of 52% and 47% respectively
• Management raised full-year revenue guidance by $500 million to $56 billion
• Strong pipeline with multiple potential approvals expected in 2025

Financial Health

• Solid balance sheet with A- credit rating
• Net debt to EBITDA ratio of 2.5x, expected to improve to 2x by 2026
• Strong free cash flow margins of 32%
• High return on equity of 56%

Analyst Sentiment Recent analyst actions suggest moderate optimism:

• Truist Securities maintains Strong Buy with $211 target (18.66% upside)
• Piper Sandler raised target to $220 (26.09% upside)
• B of A Securities initiated with Hold rating at $191 (8.38% upside)

Conclusion While ABBV's current PE ratio suggests overvaluation, the company's strong growth prospects, robust pipeline, and solid financial health indicate the premium might be justified. The stock appears fairly valued when considering:

1. Strong revenue growth from new blockbuster drugs
2. Healthy balance sheet and cash flow generation
3. Positive analyst sentiment with average upside potential
4. Diversified revenue streams reducing risk

The stock is not significantly overvalued when considering its long-term growth potential and strong market position.

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Based on the provided data and market research, here's a price prediction for ABBV stock by 2030:

ABBV stock is projected to reach $285-295 by 2030, driven by the expected $27+ billion annual sales from Skyrizi and Rinvoq by 2027 and strong performance in oncology and neuroscience segments. The company's recent acquisitions of Cerevel Therapeutics and ImmunoGen strengthen its pipeline across multiple therapeutic areas, positioning it for sustained growth despite Humira's patent expiration.

The stock's current technical setup and fundamental outlook support this long-term bullish projection, with the company maintaining strong profit margins and consistent dividend growth since 2013.

ABBV has a total of 50000 employees.